MetaCap

Cel-Sci (CVM) vs Estrella Immunopharma (ESLA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Estrella Immunopharma (ESLA) has outperformed Cel-Sci (CVM) over the past year, losing 78.9% versus a loss of 80.7%. Over five years, ESLA leads with a -96.8% price change compared with -99.6% for CVM. Cel-Sci is the larger company by market cap ($21.3 million vs $14.1 million), about 1.5 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CVM-80.67%ESLA-78.88%
+46%-23%-91%
Nov 21, 20251 yearNov 20, 2026
CVM-99.63%ESLA-96.76%
+125%+7%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CVM versus ESLA key metrics
MetricCVMESLA
Share price$1.21$0.321
Market cap$21.28M$14.11M
1-day change-17.69%-5.70%
YTD return-77.00%-79.42%
1-year return-80.67%-78.88%
5-year return-99.61%-96.78%
EPS (TTM)$-1.69$-0.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-25.41M$-13.06M
52-week high$7.80$2.27
52-week low$0.89$0.24
Distance from 52-week high-84.49%-85.86%
Analyst consensusnonenone
Avg. price target upside+933.06%+3638.32%
Average volume231.46K2.04M
Shares outstanding17.59M43.97M
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cel-Sci

CVM stock →

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

About Estrella Immunopharma

ESLA stock →

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

CVM vs ESLA FAQ

Which is bigger, Cel-Sci or Estrella Immunopharma?

Cel-Sci (CVM) is larger, with a market capitalization of $21.28M compared with $14.11M for Estrella Immunopharma (ESLA).

Which stock has performed better over the past year, CVM or ESLA?

ESLA returned -78.88% over the past 12 months, compared with -80.67% for CVM (price return, excluding dividends). Past performance does not predict future results.

Are Cel-Sci and Estrella Immunopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons